HeimLNTH • NASDAQ
add
Lantheus Holdings Inc
Við síðustu lokun
58,75 $
Dagbil
58,24 $ - 58,87 $
Árabil
47,27 $ - 111,29 $
Markaðsvirði
3,90 ma. USD
Meðalmagn
1,23 m.
V/H-hlutf.
29,88
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Tekjur | 384,01 m. | 1,39% |
Rekstrarkostnaður | 178,75 m. | 64,93% |
Nettótekjur | 27,77 m. | -78,82% |
Hagnaðarhlutfall | 7,23 | -79,11% |
Hagnaður á hvern hlut | 1,27 | -25,29% |
EBITDA | 64,02 m. | -57,55% |
Virkt skatthlutfall | 34,47% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 382,01 m. | -55,91% |
Heildareignir | 2,28 ma. | 11,06% |
Heildarskuldir | 1,16 ma. | 33,02% |
Eigið fé alls | 1,12 ma. | — |
Útistandandi hlutabréf | 66,31 m. | — |
Eiginfjárgengi | 3,48 | — |
Arðsemi eigna | 4,96% | — |
Ávöxtun eigin fjár | 6,19% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2025info | Breyting á/á |
|---|---|---|
Nettótekjur | 27,77 m. | -78,82% |
Handbært fé frá rekstri | 105,29 m. | -39,85% |
Reiðufé frá fjárfestingum | -319,47 m. | -371,21% |
Reiðufé frá fjármögnun | -99,17 m. | -5.405,83% |
Breyting á handbæru fé | -313,56 m. | -386,67% |
Frjálst peningaflæði | 89,36 m. | 54,03% |
Um
Lantheus, headquartered in Billerica, Massachusetts, is a company in the radiopharmaceuticals business. It has strategic partnerships with Bayer, Novartis, Regeneron as well as GE Healthcare and Siemens Healthineers.
Lantheus Holding, which became a NASDAQ company in 2015, is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB. Lantheus has offices in Massachusetts, New Jersey, Canada and Sweden.
Brian Markison has served as the company's CEO since March 1, 2024, following the retirement of Mary Anne Heino, who had led Lantheus for the preceding decade. Wikipedia
Stofnsett
1956
Höfuðstöðvar
Vefsvæði
Starfsfólk
808
